Plain-English translation of NCT03810196 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether CD45RA depleted peripheral stem cells — a special type of immune cell — can help children recover their immune systems faster after receiving a bone marrow transplant for leukemia. The goal is to protect patients from dangerous viral and fungal infections while still avoiding a serious complication called graft-versus-host disease (GVHD). The medication works by adding back immune memory cells that are normally removed during standard transplant preparation.
When doctors remove certain immune cells to prevent GVHD after a bone marrow transplant, they also accidentally remove protective cells that fight infections. This new treatment aims to solve that problem by carefully adding back the right immune cells to restore protection without increasing the risk of GVHD.
You likely qualify if…
You likely don't qualify if…
You will undergo standard bone marrow transplant preparation with chemotherapy and possibly radiation based on your leukemia type. After your transplant, you will receive an infusion of the special immune cells being tested, followed by short-term medication to prevent complications. You will have regular hospital visits and blood tests to monitor how well your immune system recovers and whether you develop any infections or transplant-related complications.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
United States